Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study

Avraham Karasik, Stefanie Lanzinger, Elise Chia -Hui Tan, Daisuke Yabe, Dae Jung Kim, Wayne H. -H Sheu, Cheli Melzer-Cohen, Reinhard W. Holl, Kyoung Hwa Ha, Kamlesh Khunti, Francesco Zaccardi, Anuradhaa Subramanian, Krishnarajah Nirantharakumar, Thomas Nystrom, Leo Niskanen, Majken Linnemann Jensen, Fabian Hoti, Riho Klements, Anouk Deruaz-Luyet, Moe H. KyawLisette Koeneman, Dorte Vistisen, Bendix Carstensen, Sigrun Halvorsen, Gisle Langslet, Soulmaz Fazeli Farsani, Elisabetta Patorno, Julio Nunez

Forskningsoutput: TidskriftsbidragArtikelVetenskapligPeer review

Originalspråkengelska
Artikelnummer101418
TidskriftDiabetes & metabolism
Volym49
Nummer2
Antal sidor17
ISSN1262-3636
DOI
StatusPublicerad - mars 2023
MoE-publikationstypA1 Tidskriftsartikel-refererad

Vetenskapsgrenar

  • 3121 Allmänmedicin, inre medicin och annan klinisk medicin

Citera det här